

SUPPLEMENTAL TABLE 3. Residence time of apoB in LDL subfractions as determined by metabolic studies using endogenous isotopic labeling

Reference	Subjects	Study Design <i>tracer, method administered; prandial state</i>	LDL Subfraction Isolation <i>method; density of LDL subfractions (g/ml)</i>	ApoB Residence Time <i>(day)^a</i>	
				lbLDL	sdLDL
Campos ¹	8 postmenopausal women	[D ₃]L-leucine, 14 h PCI; 3 fat-free meals 60% of calories	Sequential density uc: lbLDL <i>d</i> 1.019-1.035; sdLDL <i>d</i> 1.036-1.063	1.69 [1.16-4.55]	2.44 [1.69-4.55]
Aguilar-Salinas ²	5 FCHL	¹³ C-leucine, 8 h PCI; fasting 16 h during and after infusion	Sequential density uc: lbLDL <i>d</i> 1.019-1.035; sdLDL <i>d</i> 1.036-1.063	1.31 (0.21) ^b	5.11 (1.08) ^b
Zheng ³	12 normolipidemia (6 men, 6 women)	[D ₃]L-leucine, 15 h PCI and [D ₅] L-phenylalanine, bolus; 2 fat-free meals 60% of calories	Immunoaffinity chromatography and sequential density uc: lbLDL <i>d</i> 1.025-1.032; mLDL <i>d</i> 1.032-1.038; sdLDL <i>d</i> 1.038-1.050 ^c	0.30 ^{d,e}	0.85 ^d
	9 moderate hTG (4 men, 5 women)			0.24 ^{d,e}	1.33 ^d
Present study	6 CHL (3 men, 3 women)	[D ₃] L-leucine, 69 h bolus; 5 fat-free energy drinks per day for first 48 h.	Sequential density uc: lbLDL <i>d</i> 1.019-1.044 sdLDL <i>d</i> 1.044-1.063	1.95 (0.48) ^b	3.10 (0.36) ^b

CHL, combined hyperlipidemia; *d*, density in g/mL; FCHL, familial combined hyperlipidemia; hTG, hypertriglyceridemia; mLDL; medium LDL; PCI, primed constant infusion; uc, ultracentrifugation

^aData expressed as mean [min-max] or mean (SEM).

^bPlacebo phase only, for comparison with the other studies.

^cApoB-containing lipoproteins were separated from whole plasma by immunoaffinity chromatography according to apoC and apoE content. The 4 immunofractions were further separated by sequential density ultracentrifugation.

^dData for LDL particles containing no apoE or apoC-III which make up > 90% of total LDL.

^eMedium LDL (*d* 1.032-1.038 g/ml) RT: 0.67 days for normolipidemic subjects; 0.48 days for hypertriglyceridemic subjects.

REFERENCES

1. Campos, H., B. W. Walsh, H. Judge, and F. M. Sacks. 1997. Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women. *J. Clin. Endocrinol. Metab.* **82**: 3955-3963.
2. Aguilar-Salinas, C. A., P. H. R. Barrett, J. Pulai, X. L. Zhu, and G. Schonfeld. 1997. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy. *Arterioscler. Thromb. Vasc. Biol.* **17**: 72-82.
3. Zheng, C., C. Khoo, J. Furtado, and F. M. Sacks. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype. 2010. *Circulation.* **121**: 1722-1734.